Literature DB >> 31741730

Biochemical and microbiological evaluation of N-aryl urea derivatives against mycobacteria and mycobacterial hydrolases.

Abhishek Vartak1, Christopher Goins2, Vinicius Calado Nogueira de Moura3, Celine M Schreidah1, Alexander D Landgraf1, Boren Lin4, Jianyang Du4, Mary Jackson3, Donald R Ronning1, Steven J Sucheck1.   

Abstract

A focused library of 24 N-aryl urea derivatives was prepared and evaluated against serine esterases of Mycobacterium tuberculosis (Mtb) Rv3802c and Mtb Ag85C. The members of the library were evaluated for both selectivity and mode of inhibition. Furan-based urea derivative 6c was found to be the most potent non-covalent inhibitor of Rv3802c with a K i value of 5.2 ± 0.7 μM. On the other hand, triazole-based ureas 10a and 10b selectively inhibited Ag85C irreversibly with a k inact/K i value of 2.3 ± 0.3 and 5.5 ± 0.4 × 10-3 μM-1 min-1, respectively. The library was also evaluated for minimum inhibitory concentration (MIC) against two strains of Mtb, Mycobacterium smegmatis, and Mycobacterium abscessus. Compounds 4a and 4c were active against Mtb H37Rv mc26206 with MIC values of 3.12 and 1.5 μM, respectively. Closely related 4e showed similar activity against Mtb H37Rv mc26206 but also possessed activity against Mtb H37Ra, Mycobacterium smegmatis and Mycobacterium abscessus. Compounds 4a, 4c, and 4e all contained a common 1-(cyclohexylmethyl)-3-phenylurea motif. In summary, we identified a selective non-covalent inhibitor of Rv3802c and covalently irreversible inhibitors of Ag85C as well as the 1-(cyclohexylmethyl)-3-phenylurea motif which showed activity against a variety of mycobacteria. This journal is © The Royal Society of Chemistry 2019.

Entities:  

Year:  2019        PMID: 31741730      PMCID: PMC6677023          DOI: 10.1039/c9md00122k

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  32 in total

1.  96-well plate-to-plate gravity fluorous solid-phase extraction (F-SPE) for solution-phase library purification.

Authors:  Wei Zhang; Yimin Lu
Journal:  J Comb Chem       Date:  2007-08-15

2.  Discovery and optimization of piperidyl-1,2,3-triazole ureas as potent, selective, and in vivo-active inhibitors of α/β-hydrolase domain containing 6 (ABHD6).

Authors:  Ku-Lung Hsu; Katsunori Tsuboi; Jae Won Chang; Landon R Whitby; Anna E Speers; Holly Pugh; Benjamin F Cravatt
Journal:  J Med Chem       Date:  2013-10-23       Impact factor: 7.446

3.  Synthesis of trehalose-based compounds and their inhibitory activities against Mycobacterium smegmatis.

Authors:  Jinhua Wang; Bryan Elchert; Yu Hui; Jon Y Takemoto; Mekki Bensaci; John Wennergren; Huiwen Chang; Ravi Rai; Cheng-Wei Tom Chang
Journal:  Bioorg Med Chem       Date:  2004-12-15       Impact factor: 3.641

4.  Targeting the trehalose utilization pathways of Mycobacterium tuberculosis.

Authors:  Sandeep Thanna; Steven J Sucheck
Journal:  Medchemcomm       Date:  2015-10-16       Impact factor: 3.597

5.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.

Authors:  A Banerjee; E Dubnau; A Quemard; V Balasubramanian; K S Um; T Wilson; D Collins; G de Lisle; W R Jacobs
Journal:  Science       Date:  1994-01-14       Impact factor: 47.728

6.  Structural basis for lipid binding and mechanism of the Mycobacterium tuberculosis Rv3802 phospholipase.

Authors:  Christopher M Goins; Celine M Schreidah; Steven Dajnowicz; Donald R Ronning
Journal:  J Biol Chem       Date:  2017-12-15       Impact factor: 5.157

7.  Targeting essential cell wall lipase Rv3802c for potential therapeutics against tuberculosis.

Authors:  Parameswaran Saravanan; Hindupur Avinash; Vikash Kumar Dubey; Sanjukta Patra
Journal:  J Mol Graph Model       Date:  2012-08-04       Impact factor: 2.518

8.  Chemical genetics screening reveals KIAA1363 as a cytokine-lowering target.

Authors:  Devon M Hunerdosse; Patrick J Morris; David K Miyamoto; Karl J Fisher; Leslie A Bateman; Jonathan R Ghazaleh; Sharon Zhong; Daniel K Nomura
Journal:  ACS Chem Biol       Date:  2014-11-05       Impact factor: 5.100

9.  Novel NSAID 1-acyl-4-cycloalkyl/arylsemicarbazides and 1-acyl-5-benzyloxy/hydroxy carbamoylcarbazides as potential anticancer agents and antioxidants.

Authors:  I Perković; I Butula; M Kralj; I Martin-Kleiner; J Balzarini; D Hadjipavlou-Litina; A-M Katsori; B Zorc
Journal:  Eur J Med Chem       Date:  2012-03-03       Impact factor: 6.514

10.  Mycobacterium tuberculosis Rv3802c encodes a phospholipase/thioesterase and is inhibited by the antimycobacterial agent tetrahydrolipstatin.

Authors:  Sarah K Parker; Robert M Barkley; John G Rino; Michael L Vasil
Journal:  PLoS One       Date:  2009-01-26       Impact factor: 3.240

View more
  2 in total

Review 1.  Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.

Authors:  Anna Egorova; Mary Jackson; Victor Gavrilyuk; Vadim Makarov
Journal:  Med Res Rev       Date:  2021-03-01       Impact factor: 12.388

2.  Crystal Structures of Lignocellulosic Furfuryl Biobased Polydiacetylenes with Hydrogen-Bond Networks: Influencing the Direction of Solid-State Polymerization through Modification of the Spacer Length.

Authors:  Pierre Baillargeon; Raphaël Robidas; Olivier Toulgoat; Zacharie Michaud; Claude Y Legault; Tarik Rahem
Journal:  Cryst Growth Des       Date:  2022-04-12       Impact factor: 4.010

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.